What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
Marta Waliszewska‐Prosół, Doğa Vurallı, Paolo Martelletti
Abstract
In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment.
Topics & Concepts
MedicinePain medicineMonoclonal antibodyNeurologyCalcitonin gene-related peptideAntibodyImmunologyAnesthesiologyNeuroscienceInternal medicinePathologyPsychiatryReceptorBiologyNeuropeptideMigraine and Headache StudiesDiabetes Treatment and ManagementNeuroendocrine Tumor Research Advances